Nikon 2015 Annual Report Download - page 13

Download and view the complete annual report

Please find page 13 of the 2015 Nikon annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

11
NIKON REPORT 2015
Business Strategy
Summary for the Fiscal Year Ended March 31, 2015
Due to year-on-year increases in revenue and
prot, business successfully moved into the
black
Reviewed entry into a contract manufactur-
ing business covering cells used in regenera-
tive medicine
Market Environment
The biological microscope market in Japan was
sluggish due to a reduction in public spending
and delays in execution, but markets were
robust in the Americas and China.
In the new eld of regenerative medicine,
following a Revised Pharmaceutical Affairs Act
that came into effect in November 2014, Japan
is focusing on the early commercialization of
regenerative medicine as a seedbed for develop-
ment that holds promise.
Initiatives and Achievements
Although inuenced by the market downturn in
Japan, efforts were made to strengthen relation-
ships with customers, and market share steadily
rose. Implemented over the course of several
years, policies to improve productivity bore fruit
in the form of increased revenue and prot.
Thanks to operations in China, where market
share expanded, and in the Americas, where
sales were favorable in the cellular research-
related eld, overall sales of inverted research
microscopes were particularly strong.
With a view to launching a stem cell busi-
ness, the decision was made to enter the con-
tract manufacturing business to produce cells in
May 2015.
Summary for the Fiscal Year Ended March 31, 2015
Due to year-on-year increases in revenue and
prot, business successfully moved into the
black
Capital investment related to electronic com-
ponents, semiconductors, and automobiles
recovered, signicantly raising sales
Market Environment
Capital investment related to electronic compo-
nents, semiconductors, and automobiles recov-
ered, and expectations have become particularly
high for non-contact metrology that is capable of
smoothly measuring automobiles, aircraft, and
other structures on assembly lines. In addition,
technologies that enable both exteriors and inter-
nal structures to be measured or inspected by
generating 3D X-ray / CT images are expected to
be a growing market in the years to come.
Initiatives and Achievements
In addition to higher sales of such products as
the NEXIV Series CNC video measuring system
and the non-contact 3D metrology system, fol-
lowing a recovery in customers’ capital invest-
ment, efforts were made to further improve
productivity, and protability increased.
We are currently focusing efforts on non-
contact 3D metrology systems. These systems
represent a completely new concept by measuring
3D images using a non-contact, non- destructive
method. Designed to supersede previous systems
for measurement that required multiple units,
the non-contact 3D metrology systems enable
measurement with a single unit. The systems
demonstrate signicant advantages as a unique
Nikon technology.
Placing emphasis on cultivating the diagnostic
business, we are promoting a variety of initia-
tives toward its early commercialization.
With regard to M&A, we acquired U.K.-
based Optos Plc, a leading company in the retina
diagnostic imaging equipment market. (The
acquisition was completed and Optos became a
wholly owned subsidiary in May 2015.)
In the biomicroarray business, we are advanc-
ing technological development with a view to com-
mercialization in the United States. With regard
to the point-of-care testing (POCT) business, we
are engaged in product development through a
business alliance agreement with LSI Medience
Corporation.
Microscope Solutions Business Industrial Metrology Business Medical Business
Initiatives and Achievements
in the Fiscal Year Ended March 31, 2015